Structural modification of the antidepressant mianserin suggests that its anti-inflammatory activity may be independent of 5-Hydroxytryptamine receptors by Sacre, Sandra et al.
Structural modification of the antidepressant mianserin 
suggests that its anti­inflammatory activity may be 
independent of 5­Hydroxytryptamine receptors
Article  (Published Version)
http://sro.sussex.ac.uk
Sacre, Sandra, Jaxa-Chamiec, Albert, Low, Caroline, Chamberlain, Giselle and Tralau-Stewart, 
Cathy (2019) Structural modification of the antidepressant mianserin suggests that its anti-
inflammatory activity may be independent of 5-Hydroxytryptamine receptors. Frontiers in 
Immunology, 10 (1167). pp. 1-9. ISSN 1664-3224 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/84574/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
ORIGINAL RESEARCH
published: 24 May 2019
doi: 10.3389/fimmu.2019.01167
Frontiers in Immunology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 1167
Edited by:
Christoph Thiemermann,
Queen Mary University of London,
United Kingdom
Reviewed by:
Karolina Pytka,
Jagiellonian University, Poland
Sura Al Zoubi,
Al-Balqa‘ Applied University, Jordan
*Correspondence:
Sandra Sacre
s.sacre@bsms.ac.uk
†Deceased
Specialty section:
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology
Received: 07 February 2019
Accepted: 08 May 2019
Published: 24 May 2019
Citation:
Sacre S, Jaxa-Chamiec A, Low CMR,
Chamberlain G and Tralau-Stewart C
(2019) Structural Modification of the
Antidepressant Mianserin Suggests
That Its Anti-inflammatory Activity May
Be Independent of
5-Hydroxytryptamine Receptors.
Front. Immunol. 10:1167.
doi: 10.3389/fimmu.2019.01167
Structural Modification of the
Antidepressant Mianserin Suggests
That Its Anti-inflammatory Activity
May Be Independent of
5-Hydroxytryptamine Receptors
Sandra Sacre 1*, Albert Jaxa-Chamiec 2, Caroline M. R. Low 2, Giselle Chamberlain 1† and
Cathy Tralau-Stewart 2
1 Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom, 2Drug Discovery Centre, Imperial
College of Science, Technology, and Medicine, London, United Kingdom
Antidepressants are increasingly recognized to have anti-inflammatory properties in
addition to their ability to treat major depressive disorders. To explore if engagement
of 5-hydroxytryptamine (5-HT) receptors was required for the anti-inflammatory effect
of the tetracyclic antidepressant mianserin, a series of structural derivatives were
generated with the aim of reducing 5-HT receptor binding. Primary human peripheral
blood mononuclear cells were used to screen for anti-inflammatory activity. The lead
compound demonstrated a significant loss in 5-HT receptor binding, as assessed by
non-selective 5-HT binding of radiolabelled serotonin in rat cerebral cortex. However, it
retained the ability to inhibit endosomal toll-like receptor 8 signaling in primary human
macrophages and spontaneous cytokine production from human rheumatoid synovial
tissue equivalent to that previously observed for mianserin. These data demonstrate that
the anti-inflammatory mechanism of mianserin may be independent of 5-HT receptor
activity. This research offers new insights into the mechanism and structural requirements
for the anti-inflammatory action of mianserin.
Keywords: inflammation, toll-like receptor, rheumatoid arthritis, antidepressant, mianserin, macrophage, 5-
hydroxytryptamine, tumor necrosis factor
INTRODUCTION
Antidepressants have been used for decades in the treatment of major depressive disorders
(MDD). These drugs consist of several classes, each with varying mechanisms of action that
modulate monoaminergic signaling (1). In recent years, it has been increasingly acknowledged
that many antidepressants have an additional anti-inflammatory activity, that may contribute
toward the clinical benefit of these drugs when treating MDD (2). The pathological link
between inflammation and MDD has been established in several ways. Patients with MDD
have elevated levels of serum pro-inflammatory cytokines, which are restored to levels similar
to healthy controls in patients that respond to treatment (3). MDD can also occur as a co-
morbidity of many chronic inflammatory diseases such as rheumatoid arthritis (RA), where
cytokines are systemically elevated (4). Furthermore, data from a meta-analysis study, suggests
that the use of anti-cytokine therapies such as anti-TNF, improves depressive symptoms in
patients being treated for chronic inflammatory diseases including rheumatoid arthritis (5).
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Consequently, there has been much interest in the development
of anti-inflammatory drugs to treat MDD.
The anti-inflammatory activity of antidepressants has been
confirmed in classical models of inflammation. For example,
the selective serotonin reuptake inhibitor fluoxetine reduces
inflammation in the rat carrageenan induced paw edema model
and a murine collagen induced arthritis model (6, 7). In addition,
the atypical antidepressant mianserin which acts via a different
mechanism, as an antagonist/inverse agonist at a range of
aminergic G-protein coupled receptors (GPCRs) and inhibits
noradrenaline uptake, also ameliorates disease progression in
the murine collagen induced arthritis model and is effective
in the rat B1 kinin receptor induced paw edema model
(8, 9). Mianserin, fluoxetine and citalopram can also inhibit
spontaneous cytokine production in human synovial membrane
cultures from rheumatoid arthritis patients (7, 10).
This anti-inflammatory effect may in part be mediated
by their ability to suppress signaling downstream of the
toll-like receptor (TLR) family of innate immune receptors.
Mianserin, fluoxetine and citalopram selectively inhibit cytokine
production induced by a subset of the TLRs expressed within
the endosome, in primary human M-CSF derived macrophages,
B-lymphocytes, synovial fibroblasts and murine bone marrow
derived macrophages (7, 10). Whereas, other antidepressants
such as nortriptyline and amitriptyline have been shown to
inhibit TLR4 in rat mixed glial cultures (11).
Despite understanding that these drugs have
immunomodulatory properties, the precise mechanism remains
undefined and it is still unclear whether this is a downstream
consequence of modulating monoaminergic signaling or a
distinct property of these compounds. Our previous study in
primary human macrophages and rheumatoid synovial tissue
required concentrations far higher than those reported for 5-HT
receptor binding, indicating that the anti-inflammatory activity
may be an off target effect, distinct from the role of these drugs in
monoaminergic signaling (10, 12). However, several studies have
suggested that the anti-inflammatory activity may be partially
mediated by an increased availability of 5-HT elevating cAMP
and Ca2+ through activation of monoamine receptors (13, 14).
A better understanding of the anti-inflammatory mechanism
of antidepressants will be necessary before developing new anti-
inflammatory drugs to treat MDD and may provide a new
approach for treating chronic inflammatory diseases. In order
to verify if the anti-inflammatory activity of mianserin was
independent of 5-HT receptor binding, we designed a series of
derivatives of mianserin with the aim of reducing the affinity
for 5-HT receptors. Compounds were initially screened for their
immunomodulatory activity. Following these experiments, one
compound was identified which, despite showing a dramatically
reduced affinity for 5-HT receptors, still retained full anti-
inflammatory activity in human macrophages and human
rheumatoid synovial membrane cultures.
MATERIALS AND METHODS
Reagents
Cell culture reagents used were Penicillin-Streptomycin, RPMI
1640 obtained from Cambrex (Belgium) and fetal bovine serum
from Life Technologies Ltd (UK). The TLR ligands used were
chloroform extracted Escherichia coli (E.coli) lipopolysaccharide
(LPS) and resiquimod (R-848) from Invivogen (USA). Flagellin
(purified) and Pam3cys-ser(lys)4.3HCl (Pam3) were from Alexis
(UK). Mianserin hydrochloride was purchased from Sequoia
Research Products (Pangbourne, UK). The structural derivatives
of mianserin were synthesized by Oxygen Healthcare Research
Pvt. Ltd. (Ahmedabad, India), the synthesis steps are provided in
the Supplemental Information. Macrophage colony stimulating
factor (M-CSF) was purchased from eBioscience (USA).
Dimethyl sulfoxide (DMSO) and Hank’s balanced salt solution
(HBSS) without calium chloride and magnesium sulfate were
purchased from (Sigma, UK). Percoll Plus was purchased from
GE Healthcare (Bucks, UK), PBS citrate from Paris Anticorps
(France) and lympholyte-H from CedarLane (Ontario, Canada).
Design Hypothesis for the Structural
Modification of Mianserin
Mianserin is a tetracyclic antidepressant whose primary activity is
as an antagonist/inverse agonist of a range of aminergic GPCRs.
Literature reports include 5-HT, α-adrenergic and histamine
H1 receptor activity, but mianserin is also reported to inhibit
noradrenaline uptake (Table 1). To explore the requirement
of 5-HT receptor binding for the immunomodulatory activity
of mianserin, compounds were designed to bias activity in
favor of mianserin’s anti-inflammatory effects. In our previous
study, mianserin was observed to inhibit endosomal TLR
induced cytokine production (10). As TLRs are not known to
preferentially bind simple amines, the structure was modified in
ways that were predicted to be unlikely to bind to themonoamine
GPCRs. Although a wide range of mianserin derivatives have
previously been described, all retain the N-methyl group, which
is one of the primary pharmacophore elements for aminergic
receptor binding (16). It has long been hypothesized that
central nervous system drugs share common binding features,
principally aromatic groups and a basic amine. In the case ofMN-
1 the secondary amine was acetylated. For the other compounds,
the methyl group was removed, the basic nitrogen retained and
a polar group attached via an alkyl linker (MN-2, 3, 4, 5, and 6).
The intention was to retain inhibition of TLR-induced cytokines
but greatly reduce activity at 5-HT receptors (Figure 1).
Cell Culture
Leukocyte cones from blood donors, were purchased from NHS
Blood and Transplant (Tooting, UK). Written informed consent
was obtained from the donors by NHS Blood and Transplant
and the study was approved by Brighton and Sussex Medical
School Research Governance and Ethics Committee. Peripheral
blood mononuclear cells (PBMCs) were isolated from the cones
by Lympholyte-H centrifugation. Briefly, cells were diluted to 40
mls with HBSS, then layered onto two tubes each containing
20 mls of Lympholyte-H and centrifuged for 25min at 900 ×
g. The PBMC layer was then collected and washed twice in
HBSS by centrifugation at 350 × g for 10min. PBMCs were
cultured at 37◦C in a cell culture incubator with 5% CO2 and
21% O2. Cells were plated at 2 × 10
5 cells/well in 96-well
tissue culture plates (Corning, Amsterdam, The Netherlands) in
Roswell Park Memorial Institute (RPMI) 1640 media containing
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TABLE 1 | Reported activity of mianserin at human and rat G-protein
coupled receptors.
Receptor Activity Median pKi
human
(no. data points)
Median pKi rat
(no. data points)
5-HT1A 6.3 (1) 6.3 (1)
5-HT2A Antagonist 8.37 (7) 8.6 (5)
5-HT2B Antagonist 8.6 (2) 7.3 (1)
5-HT2C Inverse
agonist
8.36 (9) 9.13 (2)
5-HT6 Antagonist 7.3 (3) 7.4 (1)
5-HT7 Antagonist 7.43 (4) 7.4 (3)
α1A-adrenoreceptor Antagonist 7.6 (1) 7.04 (1)
α1B-adrenoreceptor Antagonist 7.4 (2) 7.18 (1)
α1D-adrenoreceptor Antagonist 7.44 (2) No data available
Histamine receptor H1 Antagonist 9.26 (2) No data available
Noradrenaline transporter Uptake
inhibitor
7.6 (1) 7.59 (3)
Activity data are from guidetopharmacology.org accessed on 31/1/19. IUPHAR/BPS
Guide to pharmacology website version 2019.1, release date 30/1/19 (15).
5-HT, 5-hydroxytryptamine.
5% (v/v) FBS and 100 U/ml penicillin/streptomycin or used for
the isolation of monocytes. Peripheral blood monocytes were
obtained by density centrifugation of PBMCs on an iso-osmotic
Percoll gradient. Iso-osmotoic percoll was achieved by adding 1
vol 1.5M NaCl to 9 vol of Percoll Plus. The gradient was then
prepared by mixing 1:1 v/v isosmotic percoll with 1x phosphate
buffered saline (PBS) citrate. Briefly, cells were diluted to 20
mls with HBSS, then layered onto a tube containing 20 mls of
iso-osmotic Percoll and centrifuged for 15min at 900 × g. The
monocyte layer was then collected and washed twice in HBSS by
centrifugation at 350× g for 10 min.
Immediately after isolation, monocytes were cultured at
37◦C in a cell culture incubator with 5% CO2 and 21%
O2. Cells were plated at 2 × 10
5 cells/well in 96-well tissue
culture plate in RPMI 1640 containing 5% (v/v) FBS and 100
U/ml penicillin/streptomycin. Macrophages were derived from
monocytes after differentiation for 4 days in RPMI containing
5% (v/v) FCS, 100 U/ml penicillin-streptomycin) and 100 ng/ml
M-CSF. Macrophages were then pre-incubated with media alone,
MN-1 or DMSO (vehicle control) for 30min, then stimulated
with 10 ng/ml LPS, 100 ng/ml PAM3cys, 100 ng/ml Flagellin or
1µg/ml R-848 for 6 h after which the supernatants were collected.
RA synovial membrane cells were isolated as previously
described (17, 18), from joint synovium removed from donors
during elective joint replacement surgery. All patients gave
written informed consent and the study was approved by
the South East Coast—Brighton and Sussex research ethics
committee (10/H1107/27). Immediately after isolation cells were
cultured at 4× 104 cells per well in a 384 well tissue culture plate
(Corning, Amsterdam, The Netherlands) in RPMI containing 5%
(v/v) FBS and 100 units/ml Penicillin/streptomycin. Cells were
then incubated in the media alone or media containing a range of
concentrations of MN-1 for 24 h. Cell viability was assessed after
FIGURE 1 | Structural derivatives of mianserin. A series of compounds were
generated based on mianserin with modification of the R group with the aim of
retaining inhibition of the anti-inflammatory action of mianserin (MN) but with
greatly reduced activity at 5-hydroxytryptamine (5-HT) receptors. In the case of
MN-1 the secondary amine was acetylated, for MN2-6 the methyl group of
mianserin was removed and replaced with polar functionalities.
all experiments by the 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) assay (Sigma) (19). Briefly, cells
were incubated with 100 µl of 0.5 mg/ml MTT in complete
cell culture medium for 4 h at 37◦C in a cell culture incubator
with 5% CO2 and 21% O2 to allow formazan crystal formation
in metabolically active cells. To dissolve the crystals, 100 µl of
MTT lysis buffer (10% SDS and 0.01M HCl) was then added
for 3 h or until all crystals had dissolved. Absorbance was read at
570 nM on a Biotek synergy HT spectrophotometric ELISA plate
reader and analyzed using the associated Gen5 software (Biotek,
Bedfordshire, UK).
ELISA (Enzyme-Linked
Immunosorbent Assay)
Sandwich ELISAs were employed to measure tumor necrosis
factor (TNF) (BD Pharmingen, UK) and interleukin (IL)-1β
(R&D systems, Abingdon, UK); TNF capture antibody (551220),
TNF biotinylated antibody (554511), IL-1β capture antibody
(MAB601), and biotinylated IL-1β antibody (BAF201) were
used according to the manufacturer’s instructions. Recombinant
TNF and IL-1β were purchased from PeproTech (London,
UK). Streptavidin HRP (DY998) was used at 1:400 dilution
and 3,3′,5,5′-Tetramethylbenzidine microwell peroxidase
substrate kit (KPL Inc., USA) was used according to the
manufacturer’s instructions. All incubation steps were for
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1 h at room temperature, apart from the incubation of the
standards and samples which was overnight at 4◦C. Color
formation was stopped using 0.16M sulfuric acid. Absorbance
was read on a Biotek synergy HT spectrophotometric
ELISA plate reader and analyzed using the associated
Gen5 software.
Non Selective Serotonin (5-HT) Receptor
Binding Assay
The affinity of MN and MN-1 toward 5-HT receptors
was determined by Eurofins Scientific France (Poitiers,
France) using radioligand binding techniques similar to
those described by Peroutka et al. (20). A non-selective
serotonin receptor binding assay was chosen due to mianserin
having activity at several of the 5-HT receptors (Table 1).
Briefly, membrane homogenates of cerebral cortex (170 µg
protein) were incubated for 60min at 37◦C with 2.5 nM
[3H]serotonin in the absence or presence of 10µM mianserin
or MN-1 in a buffer containing 50mM Tris-HCl (pH 7.4),
4mM CaCl2, 10µM pargyline and 1 g/l ascorbic acid.
Nonspecific binding is determined in the presence of 10
µM serotonin.
Following incubation, the samples were filtered rapidly under
vacuum through glass fiber filters (GF/B, Packard, Perkin Elmer,
UK) pre-soaked with 0.1% bovine serum albumin and rinsed
several times with ice-cold 50mM Tris-HCl using a 96-sample
cell harvester (Unifilter, Packard, Perkin Elmer, UK). The filters
are dried then counted for radioactivity in a scintillation counter
(Topcount, Packard, Perkin Elmer, UK) using a scintillation
cocktail (Microscint 0, Packard, Perkin Elmer, UK).
Statistical Methods
Mean, standard deviation (SD), standard error of the mean
(SEM), and statistical significance were calculated using
GraphPad version 3 (GraphPad Software Inc., USA). For
statistical analysis of multiple means a one way ANOVA with
a 95% confidence interval, followed by a Dunnett’s multiple
comparisons test was used. For the comparison of 2 means, a
two tailed t-test of paired data was used with a 95% confidence
interval. SEM was used for pooled experimental data whilst
SD was used in graphs showing representative experiments.
∗∗∗∗p < 0.0001, ∗∗p < 0.01, and ∗p < 0.05.
RESULTS
MN-1 Inhibited TLR8 Induced TNF
Production in Human PBMCs Which Was
Equivalent to Mianserin
As we had previously demonstrated an anti-inflammatory effect
of mianserin on endosomal TLR signaling, a human PBMC
assay was used to screen for activity of the structural derivatives
against TLR8 activation. R-848 was used as a ligand for TLR8;
although this is a dual ligand for TLR7, it is thought to act
solely through TLR8 in human monocytes and macrophages as
these cells do not produce TNF in response to TLR7 ligands
(10). At a set concentration of 80µM only mianserin, MN-
1 and MN-3 were able to significantly inhibit the production
of TNF upon stimulation with the TLR7/8 ligand R-848
(Figure 2A). However, MN-3 only produced a weak inhibition
that was variable between donors. Cell viability was assessed
using the MTT assay and found to be unaffected (Figure 2B).
The concentration of 80µM was chosen as a sub-optimal
inhibitory concentration for the initial screening, to permit
detection of compounds with improved inhibitory activity. This
had been determined during a previous study where 100µM
mianserin produced an almost complete inhibition of TLR8
(10). As MN-1 produced the strongest inhibitory activity, it
was chosen for further study. A dose response curve was
generated from TLR8 activated human PBMCs using a quarter
log titration to compare the EC50 of MN-1 with mianserin.
DMSO was used as a loading control at an equivalent amount
to the 100µM dose of MN-1. When the data was pooled
from three independent experiments using blood from three
separate donors, the calculated EC50 formianserin andMN-1was
37.91µM and 24.09µM respectively (Figure 2C). Dose response
curves were not generated for the other compounds, as this would
have required using significantly elevated concentrations leading
to cell toxicity.
5-HT Receptor Binding Activity of MN-1
Was Significantly Reduced in Comparison
to Mianserin
To determine if MN-1 was still capable of binding 5-HT
receptors at levels comparable to that of mianserin, the affinity
of MN-1 for 5-HT receptors (non-selective) was evaluated in
rat cerebral cortex in a radioligand binding assay. A non-
selective serotonin receptor binding assay was used due to
mianserin being reported to have activity at several 5-HT
receptors (Table 1). The activity of mianserin at 5-HT receptors
is also reported to be in the nM range, so a concentration
of 10µM mianserin and MN-1 was chosen for this assay to
ensure these inhibitors would be in excess of what is required
to block 5-HT binding (21). The rat cerebral cortex is a
useful model for these experiments, as mianserin has a similar
pKi on human and rat 5-HT receptors (Table 1). At 10µM
mianserin inhibited [3H] serotonin binding to 5-HT receptors
with an average inhibition of 94.5%, whereas MN-1 showed a
significantly decreased effect with an average inhibition of only
30% (Table 2).
TABLE 2 | MN-1 has decreased 5-HT receptor binding compared to mianserin.
Compound % Inhibition of control specific serotonin binding
Experiment 1 Experiment 2 Mean Standard deviation
Mianserin 88.9 100 94.5 7.8
MN-1 27.1 32.8 30 4
10µM Mianserin and 10µM MN-1 were measured for their ability to inhibit non selective
5-hydroxytryptamine (5-HT) binding of [3H] radiolabelled serotonin in rat cerebral cortex.
The results are expressed as a percent inhibition of the control radioligand specific binding.
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FIGURE 2 | MN-1 inhibited toll-like receptor 8 induced tumor necrosis factor (TNF) production in PBMCs that was equivalent to mianserin. (A) Peripheral blood
mononuclear cells (PBMCs) were pre-incubated with media alone unstimulated (US), dimethyl sulfoxide (DMSO) (vehicle control) or 80µM of mianserin (MN), MN-1,
MN-2, MN-3, MN-4, MN-5 or MN-6 for 30min before stimulation with 2µg/ml R-848 for 18 h. The data are shown as a percentage of the TNF production in R-848
stimulated cells from 4 to 9 independent donors. A one way ANOVA with a 95% confidence interval was used to test significance, followed by a Dunnett’s multiple
comparisons test compared to the cells stimulated with R-848 alone (****p < 0.0001 and **p < 0.01). (B) Cell viability was assessed by a 3-[4,5
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide assay. Data are representative of 3 separate experiments performed in triplicate in 3 unrelated donors. (C)
PBMCs were pre-incubated with media alone, DMSO or a quarter log titration of MN or MN-1 for 18 h. Data are shown for a representative donor and as pooled data
from three donors shown as a percentage of the TNF production from R-848 stimulated cells in the absence of MN or MN-1. Standard error of the mean was used for
pooled experimental data whilst standard deviation was used in graphs showing representative experiments.
MN-1 Retained Selectivity for Endosomal
TLRs in M-CSF Derived Primary
Human Macrophages
In our previous study, mianserin selectively inhibited the
endosomal TLRs but not those expressed at the cell surface
in primary human cells (10). To assess if this selectivity for
endosomal TLR inhibition was retained by MN-1, primary
human M-CSF macrophages were stimulated with Pam3
(TLR1/2), LPS (TLR4), and flagellin (TLR5) to activate cell
surface TLRs and R-848 to activate TLR8 localized in the
endosome. TNF production induced by the cell surface TLRs
was not inhibited by MN-1 but a dose dependent inhibition of
TLR8 induced TNF production was observed (Figure 3A). This
was significant when data was pooled from 3 separate donors
(Figure 3B). Cell viability was assessed using an MTT assay and
found to be unaffected (Figure 3C).
MN-1 Retained the Ability to Inhibit
Spontaneous Release of TNF and IL-1
From Primary Human RA Synovial
Membrane Cultures
In addition to the ability to inhibit endosomal TLRs, we
have previously published that mianserin could also inhibit
spontaneous cytokine production in human rheumatoid synovial
membrane cultures (10). These cultures spontaneously release
cytokines and matrix metalloproteases without the need for
exogenous stimulation and were used in the initial studies
that identified anti-TNF as a potential therapeutic agent for
rheumatoid arthritis (17). Incubation of MN-1 showed a dose
dependent inhibition of the spontaneous release of TNF and
IL-1 (Figure 4A). DMSO was used as a vehicle control at an
equivalent amount to the 100µM dose of MN-1. Cell viability
was assessed using the MTT assay and found to be unaffected
at all concentrations (Figure 4B). Data pooled from individual
donors showed a significant inhibition of TNF by 46.6% ±
5.1 and IL-1 by 82.2% ± 4.2 in the MN-1 treated samples
(Figure 4C).
DISCUSSION
Althoughmany studies have highlighted the immunomodulatory
properties of antidepressants and their ability to inhibit TLR
signaling, the mechanism of action remains unclear. In this
study, using structural derivatives ofmianserin the results suggest
that mianserin may modify TLR8 signaling independently of
activity at 5-HT receptors and offers an insight into the structural
requirements for the anti-inflammatory action of mianserin.
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FIGURE 3 | MN-1 inhibited toll-like receptor (TLR) 8 but not TLR1/2, 4 or 5 signaling in monocyte colony stimulating factor (M-CSF) derived macrophages. M-CSF
derived macrophages were pre-incubated for 30min with MN-1 before stimulation with 100 ng/ml Pam3cys-ser(lys)4.3HCl (Pam3) (TLR1/2), 10 ng/ml
lipopolysaccharide (LPS) (TLR4), 10 ng/ml Flagellin (TLR5), 1µg/ml resiquimod (R-848) (TLR8) or left unstimulated (US) for 6 h. (A) Data are representative of 3
separate experiments performed in triplicate in 3 unrelated donors. (B) TNF production in the presence of 100µM MN-1 is shown as a percentage of the TNF
production induced by the corresponding TLR ligand in the absence of MN-1 (shown by the dotted line as 100%). The data are pooled from 3 donors and a two tailed
t-test of paired data was used with a 95% confidence interval to compare TNF release in the presence of 100µM MN-1 compared to the same TLR ligand induced
TNF in the absence of MN-1 (*p < 0.05). The analysis was performed individually for each TLR ligand. (C) Cell viability was assessed by a 3-[4,5
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide assay. Data are representative of 3 separate experiments performed in triplicate in 3 unrelated donors.
Standard error of the mean was used for pooled experimental data whilst standard deviation was used in graphs showing representative experiments.
Antidepressants have previously been suggested to be anti-
inflammatory due to increasing the availability of 5-HT, which
then activates monoamine receptors elevating cAMP and Ca2+
(13). Although inhibition of protein kinase A (PKA), a cAMP
dependent kinase, has been shown to partially reverse the
inhibitory effect of antidepressants on TLR4 in a microglial cell
line, this was only by a modest 10–15%. In this same study,
inhibiting adenylyl cyclase that converts ATP to cAMP, had no
effect on the anti-inflammatory action of most antidepressants
tested, furthermore addition of 5-HT to these cultures did not
suppress TLR4 induced cytokine production (14). Similarly,
in rheumatoid synovial membrane cultures where mianserin
inhibits cytokine production, incubating these cultures with 5-
HT also has no effect on cytokine production (7). Together these
data suggest that although there may be a small contribution
from PKA, elevation of cAMP is probably not the main
mechanism by which antidepressants are immunomodulatory.
Indeed, the concentrations of antidepressants required to inhibit
cytokine production in primary human cells and rheumatoid
synovial tissue is far in excess of those reported for 5-HT receptor
binding (7, 10, 12).
To further investigate if 5-HT receptor binding was required
for the anti-inflammatory action of mianserin, a series of
structural derivatives were designed with the intention of
decreasing the affinity for 5-HT receptor binding. The basic
nitrogen is a key pharmacophoric component of 5-HT ligands
and we designed a set of compounds that negated its effects either
by (a) N-acylation (MN-1) or (b) tethering a polar carboxylic acid
via an alkyl chain (MN-2 to 6). TLR8 was chosen for the primary
screening in PBMCs, as this TLR produces a strong inflammatory
cytokine response that was shown in our previous studies to
be effectively inhibited by mianserin in primary human M-CSF
derived macrophages. Furthermore, the spontaneous cytokine
production fromRA cultures that was also inhibited bymianserin
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FIGURE 4 | MN-1 inhibits spontaneous production of tumor necrosis factor (TNF) and interleukin (IL)-1 from human rheumatoid arthritis (RA) synovial membrane
cultures. Human RA synovial membrane cultures were incubated for 24 h in the presence of media alone unstimulated (US) or media containing dimethyl sulfoxide
(vehicle control) or MN-1. (A) A dose response was generated using a quarter log titration of MN-1. Data are representative of 3 independent experiments from
independent donors. (B) Cell viability was assessed by a 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide assay. Data are representative of 3 independent
experiments from independent donors. (C) Pooled data is shown for 3–5 independent experiments from independent donors. All experiments were performed in
triplicate with the average plotted from each donor. Where shown as a percentage, this was calculated from the maximal spontaneous release of TNF (n = 5) or IL-1 (n
= 3) from untreated control cells. A two tailed t-test of paired data was used with a 95% confidence interval to compare cytokine release in the presence of 100 uM
MN-1 compared to spontaneous cytokine release in the absence of MN-1 (***p < 0.001; **p < 0.01) for the pooled data in part C. The analysis was performed for
each cytokine separately. Standard error of the mean was used for pooled experimental data, whilst standard deviation was used in graphs showing
representative experiments.
was thought to be partially mediated through inhibition of TLR8;
thus to test any successful derivatives in these culture it was
important to check they could still inhibit TLR8 (10).
The first approach was the most successful with the acylated
MN-1 showing the greatest inhibition of TLR8 signaling in the
PBMC assay. As no inhibition was observed when using 80µM
of the compounds in almost all of the series tethering a polar
carboxylic acid via an alkyl chain, with the exception of a very
small decrease in the case of MN-3, this strategy was not pursued
further. MN-1 however, did demonstrate a comparable inhibition
of TLR8 induced TNF production in primary human PBMCs,
with an improved EC50 compared to mianserin, despite having
a significantly reduced affinity for 5-HT receptors. Comparable
to mianserin, MN-1 also inhibited endosomal TLR8 but not
the cell surface TLRs 1/2, 4, or 5 and significantly inhibited
the spontaneous production of cytokines from the human RA
synovial membrane cultures. The spontaneous TNF production
was suppressed by an equivalent amount to that previously
published for mianserin (10).
It can therefore be postulated that inhibition of TLR8-induced
TNF and spontaneous cytokines from RA synovial cultures does
not require the presence of a basic amine but is enhanced
by the introduction of H-bond acceptors in this region of the
molecule. This data also suggested that engagement of 5-HT
receptors by mianserin may well be independent to its anti-
inflammatory activity.
Mianserin has many known off target effects, however, most
of the reported effects are at low nM concentrations. Thus,
inhibition of endosomal TLRs remains a potential mechanism
by which mianserin inhibits cytokine production in the RA
synovial membrane cultures. Our previous study suggested
that the anti-inflammatory target for mianserin may be at
the receptor level or an early signaling event, as downstream
activation of p38 mitogen activated protein kinase (MAPK)
was inhibited by mianserin (10). Although, mianserin has been
predicted using an in silico model to inhibit TLR4 signaling
by binding to MD-2 (an accessory molecule involved in TLR4
activation by LPS), this is unlikely to be the mechanism for
TLR8 inhibition, as TLR8 is not known to engage MD-2 (22).
Furthermore, at the concentrations used in our study, mianserin
does not inhibit TLR4 in primary human macrophages,
whereas we have found that other antidepressants such as
nortriptyline and amitriptyline can inhibit both TLR4 and TLR8
in human macrophages (data now shown) (10). Thus, there
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may be distinct mechanisms by which antidepressants can
inhibit TLR4 and TLR8, with some antidepressants capable of
inhibiting both.
Several events are required for the activation of endosomal
TLRs. Firstly, molecular chaperones such as GP96 and Unc93B1
transport TLRs within the cell and in particular TLR8 to the
endosomal compartment from where it can signal (23, 24). Then,
before it can become activated, endosomal acidification, and
cleavage by proteases are both necessary (25, 26). Accordingly, it
is feasible that the mechanism of inhibition of TLR8 bymianserin
and MN-1 may be through modulation of one or more of
these processes.
Limitations of this study were that only one structural
derivative of mianserin was explored in detail and that when
testing MN-1 in the non-selective 5-HT receptor binding assay,
this was performed at a single dose of 10µM rather than
generating a full dose response curve. It is possible that at a
higher concentration MN-1 may have shown greater inhibition
of 5-HT binding. However, the data indicate that MN-1 had
a reduced affinity compared to mianserin and that fact that
mianserin showed an almost complete inhibition of 5-HT
receptor binding at 10µM, yet was unable to inhibit TLR8
induced TNF at the same concentration supports the concept
of the immunomodulatory activity being distinct from 5-HT
receptor binding. It will now be important to develop a
further series of structural analogs of MN-1 and to identify the
target by which mianserin and MN-1 inhibit TLR8. However,
demonstrating that 5-HT receptor binding may not be required
for the anti-inflammatory mechanism of mianserin represents
a significant incremental step toward understanding the
structural requirements for the immunomodulatory properties
of antidepressants.
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